Data on Rosetta Genomics’ Novel Thyroid Nodule Classification Assay to be Presented at the American Association of Clinical...
May 12 2015 - 8:23AM
Business Wire
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based molecular and other diagnostics,
announces that data on the Company’s novel, microRNA-based assay
for accurate thyroid nodule classification will be presented at the
American Association of Clinical Endocrinologists 24th Annual
Scientific and Clinical Congress, being held May 12-15, 2015 in
Nashville, Tenn.
The data to be presented describes the development of a
microRNA-based test that can stratify thyroid lesions as “benign”
or “malignant” in preoperative Fine Needle Aspirate (FNA) and in
existing cytology smear samples. Following are the details of the
poster presentation:
Title:
“Development of a new microRNA-based test
for accurate thyroid nodule classification in Fine-Needle Aspirate
specimens”
Session:
Thyroid Disease
Date/Time:
Friday, May 15th from 11:00 a.m. – 12:30
p.m. Eastern Time
Location:
Third Floor - Exhibit Hall B, in the Music
City Center
Presenter:
Dganit Bar, Chief Scientific Officer of
Rosetta Genomics
Poster Number:
#1076
“We look forward to presenting data at this important symposium
attended by the leading endocrinologists who diagnose and treat
thyroid patients. Interpretation of FNA samples is not always
straightforward, which leads to an indeterminate result in up to
30% of the samples. Many patients with indeterminate results are
sent to surgery as a precaution, despite the fact the majority of
these cases are benign. This exposes patients to unnecessary
surgical risk and costs the system hundreds of millions of
dollars,” stated Kenneth A. Berlin, President and Chief Executive
Officer of Rosetta Genomics.
“We believe our novel microRNA-based assay will be highly
competitive with current testing methods, which address a total
market opportunity of greater than $350 million in the U.S. We look
forward to launching our assay in the third quarter of 2015, and
expect it will be an effective tool for the accurate diagnosis and
classification of thyroid nodules,” added Mr. Berlin.
About Rosetta Cancer Testing Services
Rosetta Cancer Tests are a series of microRNA-based diagnostic
testing services offered by Rosetta Genomics. The Rosetta Cancer
Origin Test™ can accurately identify the primary tumor type in
primary and metastatic cancer including cancer of unknown or
uncertain primary (CUP). The Rosetta Lung Cancer Test™ accurately
identifies the four main subtypes of lung cancer using small
amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately
classifies the four most common kidney tumors: clear cell renal
cell carcinoma (RCC), papillary RCC, chromophobe RCC and
oncocytoma. Rosetta’s assays are designed to provide objective
diagnostic data. In the U.S. alone, Rosetta Genomics estimates that
200,000 patients a year may benefit from the Rosetta Cancer Origin
Test™, 62,000 from the Rosetta Kidney Cancer Test™ and 222,000
patients from the Rosetta Lung Cancer Test™. The Company’s assays
are offered directly by Rosetta Genomics in the U.S., and through
distributors around the world. In addition to its proprietary
products, the Company markets the Rosetta Genomics PGxOne™ and EGFR
and KRAS tests for Admera Health. With the recent acquisition of
PersonalizeDx, the company now offers a broader menu of molecular
and other assays for lung, bladder, prostate and breast cancer
patients. For more information, please visit
www.rosettagenomics.com. Parties interested in ordering any of
these tests can contact Rosetta Genomics at (215) 382-9000 ext.
309.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based molecular diagnostics. Founded in 2000, Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. PersonalizeDx’s core
FISH, IHC and PCR-based testing capabilities and partnerships in
oncology and urology provide additional content and platforms that
complement the Rosetta offerings. Rosetta’s and PersonalizeDx’s
cancer testing services are commercially available through the
Philadelphia, PA- and Lake Forest, CA-based CAP-accredited,
CLIA-certified labs, respectively.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects, including without
limitation, statements relating to Rosetta’s development
of a microRNA test with the ability to stratify thyroid lesions as
“benign” or “malignant” in preoperative Fine Needle Aspirate (FNA)
and in existing cytology smear samples (the “Assay”), the Assay
being highly competitive with current testing methods, the market
opportunity of the Assay, the timing for the launch of the Assay,
and the Assay being an effective tool for the accurate diagnosis
and classification of thyroid nodules, constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including those risks more fully discussed in the "Risk
Factors" section of Rosetta’s Annual Report on Form 20-F for the
year ended December 31, 2014 as filed with the SEC. In
addition, any forward-looking statements represent Rosetta’s views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Rosetta does
not assume any obligation to update any forward-looking statements
unless required by law.
Company:Rosetta GenomicsKen Berlin, 609-419-9003President
& CEOinvestors@rosettagenomics.comorInvestors:LHAAnne
Marie Fields, 212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024